<DOC>
	<DOCNO>NCT00174850</DOCNO>
	<brief_summary>Anxious patient treat Selective Serotonin Reuptake Inhibitor medication ( common antidepressant ) elevate serotonin thus alleviate anxiety . These medication clearly proven efficacy upwards 70 % many anxiety disorder . In regard tolerability , major problem often produce sexual dysfunction men woman ( ie . decrease libido , anorgasmia , impotence ) upwards 30 % time . Benzodiazepine anxiolytic also FDA approve treat anxiety equal efficacy great tolerability ( little , sexual dysfunction ) . They , however , carry substantial risk addiction . Tiagabine Selective GABA Reuptake Inhibitor ( SGRI ) FDA approve treat certain type epilepsy . Like benzodiazepine , Tiagabine also increase neurotransmitter , GABA , brain think alleviate anxiety ( see reference ) way , without addiction risk common Valium-type drug . The safety profile Tiagabine think much safe . Two double blind study ongoing look Tiagabine 's effectiveness PTSD GAD . There many open label study show anxiety reduction many psychiatrist clinical practice utilize agent anxiety treatment off-label manner . This study design evaluate anxious patient take SSRI medication , reasonable response , experience significant sexual side effect push towards noncompliance possible relapse anxiety . 30 subject ( 15 men 15 woman ) ask join study place Tiagabine well current SSRI . Once acceptable dose Tiagabine reach first four week , subject ' SSRIs slowly stop . Two week enrollment , subject call order check side effect study drug insure subject titrate proper dose study drug accord study protocol . An open-label , non-placebo prospective 10 week follow occur , Tiagabine monotherapy subject follow see primarily sexual dysfunction improve anxiety remain control .</brief_summary>
	<brief_title>Switching From SSRI Tiagabine ( GABITRIL ) Order Alleviate SSRI Induced Sexual Dysfunction</brief_title>
	<detailed_description>This open-label ( placebo ) study see change SSRI Tiagabine may alleviate sexual dysfunction maintain subject non-anxious state . 30 Subjects ( least 50 % female ) currently take single SSRI least 4 week report least 50 % drop anxiety severity result . They must also report chronological emergence sexual dysfunction ( decreased sex drive , arousal , lubrication , onset impotence , anorgasmia delay ejaculation ) follow SSRI initiation . Subjects complete consent process attend screen visit give MINI psychiatric diagnostic evaluation confirm anxiety disorder , give Hamilton Anxiety Hospital Anxiety &amp; Depression Scale evaluation delineate current anxiety level ( secondary measure ) . They also complete self rat sexual health scale ASEX ass sexual functioning ( primary measure ) . Subjects undergo brief physical exam bloodwork order patient underlying medical condition warrant type medical clearance . The would hold true EKG need . Neither SSRIs , tiagabine warrant blood monitor EKGs per FDA . Assuming subject meet eligibility , start titrate upwards tolerate tiagabine downwards SSRI . Titration Tiagabine flexible typically start night Day 1 : 4 mg/day ( 2mg qAm breakfast 2mq qHS bedtime snack five day ) . On day 6 : 8mg/day ( 2mg breakfast 6mg bedtime snack ) . Day 13 : 12mg/day split dos : ( 4mg breakfast 8mg bedtime snack ) . Two week enrollment , subject call order check side effect study drug insure subject titrate proper dose study drug accord study protocol . At discretion investigator , dose may lower alleviate side effect . Vist 2 occur end week 4 SSRI optimal tiagabine place . All scale except MINI complete . Vist 3 occur end week 8 scale complete . Visit 4 final visit end week 14 , scale , PE blood/EKG collect warrant . The efficacy safety Tiagabine evaluate throughout treatment period ( see flow chart ) . At end study , subject may opt continue tiagabine titrate back SSRI . Our team also liaison subject 's prescriber ensure follow continuity care study exit .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Tiagabine</mesh_term>
	<criteria>Patients include study follow criterion meet : 1 . Written inform consent obtain . 2 . The patient Englishspeaking 18 64 year age inclusive . 3 . The patient meet DSMIV criterion generalize anxiety disorder determine MINI psychiatric evaluation . 4 . The patient currently respond take monotherapy SSRI ( include venlafaxine ) ≥ 4 week stable , adequate therapeutic ≥ 4 week 5. patient report clear sexual side effect post date SSRI start 6 . The patient total score le 18 HAMA scale ( ) The patient good health determine medical psychiatric history , medical examination , ( j ) Women must nonchildbearing potential [ i.e. , postmenopausal , surgically sterile ( hysterectomy tubal ligation ) ] must meet following condition : use reliable , medically accept form contraception least 60 day baseline visit , agree continue use throughout duration study 30 day final dose study drug . Reliable form contraception include oral , implanted , injected contraceptive ; intrauterine device place least 3 month ; adequate barrier method conjunction spermicide ( abstinence consider acceptable contraceptive regimen ) . Women must give pregnancy test ( ßHCG ) , unless least 2 year postmenopausal surgically sterile , result test must negative . ( k ) The patient must willing able comply study restriction remain clinic require duration study period , willing return clinic followup evaluation specify protocol . Patients exclude participate study 1 follow criterion meet : 1 . Other current mental illness/disorder 2 . The patient significant risk suicide ( ) The patient history great one previous depressive episode remission &gt; 1 year ( e ) The patient take sildenafil sexually enhance agent ( f ) The patient serious , unresolved unstable medical and/or psychiatric condition ( treat untreated ) . ( g ) The patient previously participate clinical study GABITRIL treat GABITRIL . ( h ) The patient pregnant lactate woman ( woman become pregnant study withdrawn study ) . ( l ) The patient use investigational drug within 1 month screen visit participate concurrent clinical trial . ( ) The patient disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) explainable medical condition cause sexual dysfunction ( n ) The patient alcohol sedative dependence within last one year illegal substance abuse/dependence last 3 month include heavy caffeine , nicotine use contribute anxiety state ( ) The patient unlikely comply study protocol , unreliable provide rating , unsuitable reason , judge investigator . ( p ) The patient clinically significant deviation normal physical examination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>anxiety</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>ssri</keyword>
</DOC>